What is BioAtla?
BioAtla is at the forefront of developing innovative biologics through its proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These technologies, protected by an extensive patent portfolio, are designed to create superior monoclonal antibodies with enhanced tumor targeting selectivity and improved manufacturability. The company's focus on precise targeting of the tumor microenvironment (TME) aims to improve therapeutic indices, potentially leading to better safety profiles and enabling the treatment of previously intractable cancers.
How much funding has BioAtla raised?
BioAtla has raised a total of $547.7M across 9 funding rounds:
Debt
$5.8M
Private Equity
$39M
Series C
$45M
Series B
$84M
Series A
$37M
Multiple Rounds
$261.9M
Share Placement
$75M
Debt (2014): $5.8M, investors not publicly disclosed
Private Equity (2015): $39M, investors not publicly disclosed
Series C (2016): $45M supported by Global BIO Impact Fund
Series B (2016): $84M, investors not publicly disclosed
Series A (2017): $37M backed by SunTerra Capital, F1 BioVentures LLC, and Sinobioway Group
Debt (2020): $350K with participation from PPP
Series D (2020): $72.5M led by Pfizer Ventures, Pappas Capital, Janus Henderson Investors, Boxer Capital, Farallon Capital Management , L.L.C., Cormorant Asset Management , LLC, Soleus Capital, and HBM Healthcare Investments AG
Stock Issuance/Offering (2020): $189M, investors not publicly disclosed
Share Placement (2021): $75M featuring Great Point Partners and Deerfield
Key Investors in BioAtla
Great Point Partners
Great Point Partners is a leading health care investment firm with a focus on biopharmaceutical services and supplies, pharmaceutical infrastructure, and IT-enabled health care businesses. They provide growth equity and financing to growing health care companies.
Deerfield
Deerfield Management is an investment firm dedicated to advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models and driving innovation.
Pfizer Ventures
Pfizer Ventures is the venture capital arm of Pfizer, a global biopharmaceutical company focused on researching, developing, and manufacturing medicines and vaccines across various therapeutic areas, including oncology.
What's next for BioAtla?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions BioAtla for accelerated growth and the advancement of its therapeutic pipeline. This significant backing suggests a strong investor confidence in the company's technology and its potential to address unmet needs in oncology. Future strategic initiatives will likely focus on clinical development, regulatory approvals, and potential commercialization of its CAB-based therapeutics, further solidifying its position in the biopharmaceutical sector.
See full BioAtla company page
